The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
May 1st 2024
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
Subcutaneous Trastuzumab May Offer Benefits Over Standard IV Infusion in Patients With Breast Cancer
A new formulation of trastuzumab that is administered subcutaneously appears to be as effective as the approved bodyweight-based intravenous regimen in women with HER2-positive breast cancer.